DK2139483T3 - Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer - Google Patents

Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer

Info

Publication number: DK2139483T3
Authority: DK; Denmark
Prior art keywords: pi3k; quinoxaline; cancer; inhibitor; alpha
Prior art date: 2007-04-11

Application number

DK08742674.8T

Other languages

English (en)

Inventor

Peter Lamb

David Matthews

Original Assignee

Exelixis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-11

Filing date

2008-04-08

Publication date

2014-01-13

2008-04-08 Application filed by Exelixis Inc filed Critical Exelixis Inc

2014-01-13 Application granted granted Critical

2014-01-13 Publication of DK2139483T3 publication Critical patent/DK2139483T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK08742674.8T 2007-04-11 2008-04-08 Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer DK2139483T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US92316407P	2007-04-11	2007-04-11
PCT/US2008/004570 WO2008127594A2 (en)	2007-04-11	2008-04-08	Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer

Publications (1)

Publication Number	Publication Date
DK2139483T3 true DK2139483T3 (da)	2014-01-13

Family

ID=39864581

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK08742674.8T DK2139483T3 (da)	2007-04-11	2008-04-08	Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer

Country Status (33)

Country	Link
US (1)	US8481001B2 (da)
EP (1)	EP2139483B9 (da)
JP (2)	JP5726515B2 (da)
KR (1)	KR101586774B1 (da)
CN (2)	CN103202842A (da)
AU (1)	AU2008239668B2 (da)
BR (1)	BRPI0810208A2 (da)
CA (1)	CA2684056A1 (da)
CO (1)	CO6140024A2 (da)
CR (1)	CR11099A (da)
CY (1)	CY1114608T1 (da)
DK (1)	DK2139483T3 (da)
EA (1)	EA019064B1 (da)
EC (1)	ECSP099723A (da)
ES (1)	ES2438998T3 (da)
GT (1)	GT200900263A (da)
HR (1)	HRP20131081T1 (da)
IL (1)	IL201211A (da)
MA (1)	MA31335B1 (da)
ME (1)	ME00937B (da)
MX (1)	MX2009010929A (da)
MY (1)	MY150797A (da)
NI (1)	NI200900184A (da)
NZ (1)	NZ580009A (da)
PL (1)	PL2139483T3 (da)
PT (1)	PT2139483E (da)
RS (1)	RS53020B (da)
SI (1)	SI2139483T1 (da)
SV (1)	SV2009003390A (da)
TN (1)	TN2009000399A1 (da)
UA (1)	UA98141C2 (da)
WO (1)	WO2008127594A2 (da)
ZA (1)	ZA200906765B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1940839B1 (en) *	2005-10-07	2013-07-31	Exelixis, Inc.	PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
WO2007044729A2 (en) *	2005-10-07	2007-04-19	Exelixis, Inc.	N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
ATE539752T1 (de)	2006-08-16	2012-01-15	Exelixis Inc	Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
ES2430614T3 (es) *	2007-04-10	2013-11-21	Exelixis, Inc.	Métodos de tratamiento del cáncer usando inhibidores de piridopirimidinona de PI3K alfa
JP5687903B2 (ja) *	2008-11-10	2015-03-25	協和発酵キリン株式会社	キヌレニン産生抑制剤
DE102009049679A1 (de)	2009-10-19	2011-04-21	Merck Patent Gmbh	Pyrazolopyrimidinderivate
AR080151A1 (es)	2010-02-09	2012-03-14	Exelixis Inc	Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
UY33498A (es)	2010-07-09	2013-01-03	Sanofi Aventis	Combinaciones de inhibidores de quinasas para el tratamiento de cancer
AU2011302196B2 (en)	2010-09-14	2016-04-28	Exelixis, Inc.	Inhibitors of PI3K-delta and methods of their use and manufacture
CA2815107A1 (en)	2010-10-20	2012-04-26	Merck Serono S.A. Geneva	Method for preparing substituted n-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates n-(3-chloro-quinoxalin-2-yl)sulfonamides
DE102010048800A1 (de)	2010-10-20	2012-05-10	Merck Patent Gmbh	Chinoxalinderivate
DE102010049595A1 (de)	2010-10-26	2012-04-26	Merck Patent Gmbh	Chinazolinderivate
WO2012065057A2 (en)	2010-11-12	2012-05-18	Exelixis, Inc.	Phosphatidylinositol 3-kinase inhibitors and methods of their use
IN2014CN02671A (da) *	2011-09-14	2015-07-03	Exelixis Inc
CA2850763A1 (en) *	2011-10-04	2013-04-11	Gilead Calistoga Llc	Novel quinoxaline inhibitors of pi3k
WO2013056067A1 (en)	2011-10-13	2013-04-18	Exelixis, Inc.	Compounds for use in the treatment of basal cell carcinoma
JP2014532647A (ja) *	2011-10-28	2014-12-08	ノバルティスアーゲー	消化管間質腫瘍を治療する方法
AU2012332486A1 (en) *	2011-11-01	2014-06-19	Arthur Decillis	N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies
WO2013067306A1 (en) *	2011-11-02	2013-05-10	Exelixis, Inc.	Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
US20150010545A1 (en) *	2011-12-27	2015-01-08	Kadmon Corporation, Llc	Methods for treatment of breast cancer nonresponsive to trastuzumab
WO2013152717A1 (zh)	2012-04-10	2013-10-17	上海昀怡健康管理咨询有限公司	稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
EP2882722B1 (en)	2012-08-13	2016-07-27	Takeda Pharmaceutical Company Limited	Quinoxaline derivatives as gpr6 modulators
US9745321B2 (en)	2013-09-30	2017-08-29	Shanghai Yingli Pharmaceutical Co., Ltd	Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
CN104557872B (zh)	2013-10-16	2017-05-24	上海璎黎药业有限公司	稠合杂环化合物、其制备方法、药物组合物和用途
JP6526034B2 (ja)	2014-02-14	2019-06-05	武田薬品工業株式会社	Ｇｐｒ６のピリドピラジンモジュレーター
US9950194B2 (en)	2014-09-09	2018-04-24	Mevion Medical Systems, Inc.	Patient positioning system
WO2019119206A1 (en) *	2017-12-18	2019-06-27	Merck Sharp & Dohme Corp.	Purine inhibitors of human phosphatidylinositol 3-kinase delta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1599196A4 (en) *	2003-01-17	2006-05-31	Threshold Pharmaceuticals Inc	COMBINATION THERAPIES FOR CANCER TREATMENT
JP5226513B2 (ja) *	2005-08-26	2013-07-03	メルクセローノソシエテアノニム	ピラジン誘導体及びその使用
WO2007044729A2 (en) *	2005-10-07	2007-04-19	Exelixis, Inc.	N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
EP1940839B1 (en)	2005-10-07	2013-07-31	Exelixis, Inc.	PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
ATE539752T1 (de)	2006-08-16	2012-01-15	Exelixis Inc	Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
ZA200904857B (en)	2007-02-22	2010-09-29	Merck Serono Sa	Quinoxaline compounds and use thereof
ES2430614T3 (es)	2007-04-10	2013-11-21	Exelixis, Inc.	Métodos de tratamiento del cáncer usando inhibidores de piridopirimidinona de PI3K alfa
JP4623164B2 (ja) *	2008-08-21	2011-02-02	セイコーエプソン株式会社	プロジェクタ

2008
- 2008-04-08 RS RS20130486A patent/RS53020B/sr unknown
- 2008-04-08 CN CN2013101161222A patent/CN103202842A/zh active Pending
- 2008-04-08 HR HRP20131081AT patent/HRP20131081T1/hr unknown
- 2008-04-08 PL PL08742674T patent/PL2139483T3/pl unknown
- 2008-04-08 US US12/595,236 patent/US8481001B2/en not_active Expired - Fee Related
- 2008-04-08 WO PCT/US2008/004570 patent/WO2008127594A2/en not_active Ceased
- 2008-04-08 PT PT87426748T patent/PT2139483E/pt unknown
- 2008-04-08 EA EA200970935A patent/EA019064B1/ru not_active IP Right Cessation
- 2008-04-08 ME MEP-2009-304A patent/ME00937B/me unknown
- 2008-04-08 NZ NZ580009A patent/NZ580009A/xx not_active IP Right Cessation
- 2008-04-08 KR KR1020097023536A patent/KR101586774B1/ko not_active Expired - Fee Related
- 2008-04-08 EP EP08742674.8A patent/EP2139483B9/en active Active
- 2008-04-08 DK DK08742674.8T patent/DK2139483T3/da active
- 2008-04-08 AU AU2008239668A patent/AU2008239668B2/en not_active Ceased
- 2008-04-08 ES ES08742674.8T patent/ES2438998T3/es active Active
- 2008-04-08 MY MYPI20094215 patent/MY150797A/en unknown
- 2008-04-08 CA CA002684056A patent/CA2684056A1/en not_active Abandoned
- 2008-04-08 CN CN2008800173944A patent/CN101959516B/zh not_active Expired - Fee Related
- 2008-04-08 SI SI200831061T patent/SI2139483T1/sl unknown
- 2008-04-08 UA UAA200911452A patent/UA98141C2/ru unknown
- 2008-04-08 MX MX2009010929A patent/MX2009010929A/es active IP Right Grant
- 2008-04-08 JP JP2010503043A patent/JP5726515B2/ja active Active
- 2008-04-08 BR BRPI0810208-2A2A patent/BRPI0810208A2/pt not_active IP Right Cessation
2009
- 2009-09-29 IL IL201211A patent/IL201211A/en active IP Right Grant
- 2009-09-29 ZA ZA200906765A patent/ZA200906765B/xx unknown
- 2009-09-30 TN TNP2009000399A patent/TN2009000399A1/fr unknown
- 2009-10-09 GT GT200900263A patent/GT200900263A/es unknown
- 2009-10-09 NI NI200900184A patent/NI200900184A/es unknown
- 2009-10-09 SV SV2009003390A patent/SV2009003390A/es unknown
- 2009-10-30 MA MA32313A patent/MA31335B1/fr unknown
- 2009-11-09 EC EC2009009723A patent/ECSP099723A/es unknown
- 2009-11-09 CR CR11099A patent/CR11099A/es unknown
- 2009-11-09 CO CO09126923A patent/CO6140024A2/es unknown
2013
- 2013-11-01 JP JP2013228684A patent/JP2014074031A/ja active Pending
- 2013-11-15 CY CY20131101016T patent/CY1114608T1/el unknown

Also Published As

Publication number	Publication date
EA019064B1 (ru)	2013-12-30
WO2008127594A2 (en)	2008-10-23
EP2139483B1 (en)	2013-09-18
GT200900263A (es)	2014-01-15
PT2139483E (pt)	2013-12-27
CN101959516A (zh)	2011-01-26
CN103202842A (zh)	2013-07-17
MA31335B1 (fr)	2010-04-01
BRPI0810208A2 (pt)	2014-10-21
EP2139483B9 (en)	2014-05-21
CR11099A (es)	2010-01-19
AU2008239668B2 (en)	2013-11-07
UA98141C2 (ru)	2012-04-25
NZ580009A (en)	2012-06-29
SV2009003390A (es)	2010-05-21
CN101959516B (zh)	2013-05-08
HRP20131081T1 (hr)	2013-12-20
JP2014074031A (ja)	2014-04-24
JP5726515B2 (ja)	2015-06-03
ECSP099723A (es)	2010-03-31
IL201211A (en)	2015-09-24
EP2139483A2 (en)	2010-01-06
IL201211A0 (en)	2010-05-31
CY1114608T1 (el)	2016-10-05
MX2009010929A (es)	2010-01-20
MY150797A (en)	2014-02-28
WO2008127594A3 (en)	2009-04-30
US8481001B2 (en)	2013-07-09
HK1140141A1 (en)	2010-10-08
ES2438998T3 (es)	2014-01-21
NI200900184A (es)	2011-09-08
AU2008239668A1 (en)	2008-10-23
US20110123434A1 (en)	2011-05-26
CA2684056A1 (en)	2008-10-23
PL2139483T3 (pl)	2014-02-28
EA200970935A1 (ru)	2010-04-30
ZA200906765B (en)	2010-05-26
SI2139483T1 (sl)	2013-11-29
KR101586774B1 (ko)	2016-01-19
CO6140024A2 (es)	2010-03-19
RS53020B (sr)	2014-04-30
TN2009000399A1 (fr)	2010-12-31
KR20100019436A (ko)	2010-02-18
ME00937B (me)	2012-06-20
JP2010523669A (ja)	2010-07-15

Publication	Publication Date	Title
DK2139483T3 (da)	2014-01-13	Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer
DK3517534T3 (da)	2024-05-27	Forbindelser, der er anvendelige til behandling af cancer
DK3567035T3 (da)	2022-09-05	N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
DK2205257T3 (da)	2013-12-02	Doseringsforskrifter for LAG-3Ig (IMP321) til anvendelse ved behandling af cancer
DK2195015T3 (da)	2017-06-19	Sammensætning til behandling af prostatacancer
CL2007002783S1 (es)	2008-07-04	Inhalador multidosis.
DK2101805T3 (da)	2013-01-21	Integrinligander til anvendelse i behandling af cancer
DK3289876T3 (da)	2022-10-10	Forbindelser til behandling af cancer
DK2154971T3 (da)	2012-04-02	Synergistisk farmaceutisk kombination til behandling af cancer
DK2233135T3 (da)	2012-10-01	Anvendelse af en betablokker til fremstilling af et medikament til behandling af hæmangiomer
BRPI0814889A2 (pt)	2017-05-23	tratamento com ligantes alfa7-seletivos.
DK2504005T3 (da)	2014-01-13	Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
EP2114498A4 (en)	2010-08-25	INHALER
EP2142239A4 (en)	2014-12-24	INHALATION DEVICE
EP2195010A4 (en)	2012-03-14	TREATMENT WITH INHIBITORS OF KALLIKREINE
EP2131904A4 (en)	2013-11-06	Dose counter
DK2144905T3 (da)	2013-03-11	Terapeutiske midler
BRPI0814736A2 (pt)	2017-06-06	inalador.
BRPI0813670A2 (pt)	2014-12-30	Compostos para tratamento
DK2235002T3 (da)	2013-03-11	4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
DK2173831T3 (da)	2012-09-17	Brøndbehandling
BRPI0818170A2 (pt)	2017-05-16	5-cianotienopiridinas para o tratamento de tumores.
DK2033675T3 (da)	2014-09-08	Inhalationsapparat
BRPI0820410A2 (pt)	2015-05-19	Lactans substituídos terapêuticos
BRPI0818598A2 (pt)	2017-05-16	agentes terapêuticos - 802